Infection and Drug Resistance (Jan 2022)
COVID-19 Associated Bacteremia with Chryseobacterium indologenes Co-Harboring blaIND-2, blaCIA and blaCcrA
Abstract
Ting-Kuang Yeh,1 Zong-Hao Li,2 Yao-Ting Huang,2 Po-Yu Liu1,3,4 1Division of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 2Department of Computer Science and Information Engineering, National Chung Cheng University, Chiayi, Taiwan; 3Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; 4Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, TaiwanCorrespondence: Po-Yu LiuDivision of Infectious Diseases, Department of Internal Medicine, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan, Tel +886-4-23592525-3329, Fax +886-4-23592525-83588, Email [email protected]: We report a COVID-19 case with carbapenem resistant Chryseobacterium indologenes bacteremia. Whole genome sequencing identified the presence of blaIND-2, blaCIA and blaCcrA. To our knowledge, this is the first report of Chryseobacterium indologenes complicating COVID-19 and the detection of blaCcrA in C. indologenes. The presence of blaCcrA in Chryseobacterium was overlooked previously may related to substantial sequence divergence with the original allele in Bacteroides fragilis. Antimicrobial resistance (AMR) is a challenge to global health in the age of COVID-19 pandemic. Further study and surveillance of underlying mechanisms is needed.Keywords: COVID-19, SARS-CoV-2, Chryseobacterium indologenes, resistance
